International Journal of Pharmaceutical Research and Applications
Volume 11, Issue 1 Jan - Feb 2026, pp: 544-550 www.ijprajournal.com ISSN: 2456-4494

Immunological Breakthroughs the Global approaches in Viral Vector Based vaccinum and Sera against Cancer: A Cross Disciplinary Review

Dr.Mrs.Sudha Rathod[(1)] , Ms.Anjali Rai[(2)], Ms. Khushi B. Chaubey[(3*)], Ms. Pallavi B. Hase[(4)], Mr. Karan K. Singh[(5)].

(1) Principal, Oriental College Of Pharmacy
(2) Assistant Professor, Oriental College Of Pharmacy
(3) , (4), (5) Research Scholar, Oriental College Of Pharmacy
Corresponding Author: Ms.Khushi Bhupendra Chaubey, Research Scholar,, Oriental College Of Pharmacy,

Date of Submission: 25-01-2026 Date of Acceptance: 05-02-2026

ABSTRACT

The development of vaccines for cancer and other chronic diseases represents a larger advancement in the modern medicine and public health, aiming to address conditions that have had significant impacts on the worldwide morbidity and mortality. This article presents a comprehensive overview of the history, epidemiology in detail pathology for various diseases, with precise emphasis with the scientific basis of vaccine technologies. It classified into different types of vaccines including mRNA, vectors, protein units, DNA vaccines and inactivated vaccines highlighting how they are designed, produced and how they function within the body immune system.[1]

Key components that are used to make vaccines, like lipid nanoparticles, antigens, and adjuvants, are discussed to explain how body immune responses are initiated and sustained. The article outlines the therapeutic potential and proven efficacy of vaccines in the preventing and mitigating diseases such as HPV related cancers, hepatitis B (which can also lead to various cancer-like liver) emerging immunotherapies to individualized cancer vaccines.[2]

The article examines the recognized side effects and serious long term adverse reactions associated with these vaccines, covering both short-term and long-term outcomes. It also delves into the ongoing challenges related to vaccine access and distribution, such as global equity, public skepticism, logistical barriers and also the high-cost amount of some advanced therapeutic vaccines. Review aims an offer a nuanced understanding of the landscape beyond COVID19, providing valuable insight for future health research, clinical development and health policy formulation.[3]

Keywords: Cancer, HPV, hepatitis B, immunotherapy, mRNA,deactivated vaccine, protein unit, DNA sera, immunity, tumour antigens, booster dose, sera development.

I. INTRODUCTION

Over recent decades, advancements in various vaccine technology had expanded above serious infectious diseases to target chronic illnesses and cancers. These developments represent a pivotal shift in medical innovation, as scientists now harness immunological approaches to treat conditions once thought untreatable with vaccines. The emergence of cancer vaccines and those for other diseases such as hepatitis B, HPV, and certain illnesses has highlighted importance an understanding disease pathology, immune response, and technological innovation. Creating vaccines for noninfectious conditions, especially cancer, requires extensive research into tumour biology, antigen selection, the molecular principles driving disease process. The study explores the diverse various different type of vaccines developed for tumour cancer and other diseases, the scientific methods and materials used in their formulation, their effectiveness in preventing or treating illness, potential side effects, and the international efforts to ensure equitable access to these lifesaving treatments.[4]

Vaccines

Vaccines are one of the most significant impacts in modern medicine. They function by priming our immune systems to identify and neutralize harmful agents before they can cause serious illness. In the case of cancer and chronic diseases, vaccines act by identifying unique target like cancer tumour associated antigens to boost the body's natural defenses. There are various types of these vaccines, add mRNA, various viral vector, DNA, inactivated and protein unit vaccines, each uniquely designed for boost immune system against disease targets. Their advantages extend beyond individual protection: by lowering disease incidence and also lessen various burden on healthcare systems and prevent long term complications. Moreover, preventive vaccines like those for HPV and hepatitis B have already shown important success in decreasing cancer rates. Therapeutic vaccines, an emerging field oncology, aim for cure past conditions by strengthening body immunity response. These innovations reflect the growing potential of vaccines not only to prevent but also to treat complex diseases demonstrating their indispensable role in advancing public health worldwide.[5]

SERA

Sera in Cancer and Disease Research Serathe clear, antibodyrich fluid left behind after blood clotsare critical not only in infectious disease management but also in the diagnosis and treatment of cancer and other noncommunicable diseases. While sera lack clotting proteins like fibrinogen, they are abundant in immunoglobulins, cytokines, and other biomarkers that offer insights into immune status. In oncology, serological testing plays a key role in identifying tumour markers, identifying pharmacological result for predicting recurrence. Researchers follow up study on cancer patient to study immune data to cancer, test the effectiveness of therapeutic antibodies, and design new sera platforms. Therapeutically, sera-based interventions like monoclonal antibody approaches and antiserum derived immunotherapies are paving way by being more personalized and targeted cancer tumour treatments. These advances reaffirm sera's central role in translational medicine, particularly as we move toward precision oncology and immune based interventions.[6]

Cancer Vaccine Development: A Brief History

1. Identification of Cancer as an Immunological Target (Mid20th Century Early 2000s)

While vaccines traditionally connected with infectious diseases, idea of targeting cancer through immunization dates past decades. Mid20th century, scientists began exploring concept that cancer cells might display unique antigens tumour associated antigens (TAAs)that could be recognized by the immune system. Pioneering experiments using irradiated cancer cells or bacterial adjuvants suggested at the possibility of inducing antitumor immunity. However, lack of specificity and complexity of cancer biology limited studies or research. It wasn't until the identification of specific TAAs like HER2, PSA, and MUC1 that vaccine development gained momentum. These discoveries laid the framework for both prevention and therapeutic vaccine strategies.[7]

2. Cancer diseases Vaccines: Prevention Before therapy

The breakthrough in injection formulation came with the creation of shots for virus induced cancers. Hepatitis B (HBV) vaccine, licensed 1980s, was the first vaccine proven to prevent a form of cancer liver.[8] This success followed by the formulating of the HPV (human papillomavirus) shots Gardasil and Cervarix which were approved in the mid2000s to prevent cervical, anal, and other HPV associated cancers. These vaccines introduced virus like particles (VLPs) that mimic HPVs outer shell, prompting a strong antibody response without using live virus. Their widespread use has led sharp declines in the cervical tumour cancer incidence populations.[9]

3. Cancer Vaccines: Training in Immune System for Attack Tumors

FDA approved therapeutic vaccine was SipuleucelT (Provenge), licensed in the 2010 for prostate cancer. The uses a patient's own dendritic cells, exposed to a fusion protein of prostatic acid phosphatase (PAP) and GMCSF, to prime strong system towards prostate cancer antigens.[10] Other strategies include peptide-based vaccines, which introduce small segments of tumour antigens; DNA/RNA based vaccines, which encode various cancer tumour proteins; and viral vector vaccines, which use harmless viruses to provide cancer specific genes into cells. Many are under active development for glioblastoma, pancreatic tumour, and more. The mRNA various vaccine platform, proven during the COVID19 pandemic, is being rapidly adapted for create individualized vaccines tailored to for each patient's distinct tumour mutations. [11]

4. Current Trials Future Directions (2020s Beyond)

As 2020s, vaccines are various stages of clinical trials, often in mixture with various checkpoint inhibitors, radiation, or chemotherapy. Advances in next generation sequencing, machine learning, and bioinformatics have enabled the identification of neoantigens mutations found only in tumour cellsas precise vaccine targets. Companies and research institutions are also working on off-the-shelf vaccine platforms that can be quickly customized for different tumour types or patient profiles. While no universal therapeutic cancer vaccine has yet matched the impact of infectious disease vaccines, progress is accelerating. Researchers are now exploring vaccines for cancers of the lung, pancreas, breast, and brain. The success of these efforts will likely hinge on personalized medicine, combination treatment, and enhances understanding of the tumour microenvironment.[12]

5. Global immunization Efforts and Challenges (2021)

By 2021, landscape of immunization had expanded beyond infectious diseases to include cancer prevention, with sera like HPV and hepatitis B widely adopted in standard global immunization programs. However, despite their proven effectiveness in preventing virus associated cancers such as various cancer-like liver and cervical, global 9-09-2025 https://www.checkforplag.com Page 5/12 uptake remained uneven. Many regions especially in low and middle-income countries faced barriers including limited healthcare infrastructure, vaccine cost, cultural taboos surrounding cancer and sexual health, and widespread misinformation. For example, HPV vaccine hesitancy in some areas was driven by myths linking it to infertility or encouraging promiscuity. Distribution hurdles were also significant: cold chain requirements, inadequate funding, and prioritization of more immediate public concerns made by using vaccine for cancer rollout challenging. Global organizations, adding WHO, Gavi, and UNICEF, made significant efforts for promote education through initiatives like the HPV Vaccine Acceleration Program. These efforts aimed close gap in vaccine access and also reduce world cancer burden, particularly for women and children. However, persistent challenges in awareness, healthcare access, and political will continued to impact the speed and success of cancer vaccination campaigns. These issues underscored the critical need for advocacy, world cooperation, and community engagement to overcome stigma and logistical barriers.[13] children. However, persistent challenges in awareness, healthcare access, and political will continued to impact the speed and success of cancer vaccination campaigns. These issues underscored the critical need for advocacy, world cooperation, and community engagement to overcome stigma and logistical barriers.[13]

6. Adapting Tumour Diversity and Vaccine Optimization (20222023)

Unlike diseases with the higher stable targets, cancers present a unique challenge due to their genetic diversity and ability to evolve within each patient. Between 2022 and 2023, research began to focus heavily on personalized cancer vaccines, particularly using mRNA platforms. These vaccines are tailored to a patient's individual tumour mutations known as neoantigens and aim to train the immune system to recognize and attack cancer cells without harming healthy tissue. As studies revealed that evade immune detection, scientists worked on refining vaccine formulations to ehances their specificity, longevity, and delivery.Strategies such as heterologous prime boost regimens where patients receive different types of vaccines for enhanced immunity began to show promise.[14] Researchers also explored combination therapies, pairing cancer vaccines with immune checkpoint inhibitors (like antiPD1 or CTLA4 antibodies) to overcome tumour induced immunosuppression. Additionally, attention turned to optimizing vaccine delivery via nanoparticles, viral vectors and platforms to impart robust and sustained responses.

These developments highlighted complexity of designing cancer related vaccines and the importance of continuously adapting scientific strategies to keep up alomg tumour evolution, just as vaccine developers adapted to emerging SARSCoV2 variants.[15]

7. Ongoing Research and Future Directions (20242025)

Looking ahead, the future of cancer vaccines lies in customization, accessibility, and integration into broader public health strategies. Researchers are actively developing next generation cancer vaccines that aim to provide long-lasting, comprehensive protection against a wider range of cancers, not just those caused by viruses. This includes attempts to create pantumour vaccines capable of target antigens across different cancer types. Innovative delivery methods are also gaining momentum. Nasal drug delivery and also oral various vaccine formulations are being investigated for ability to stimulate immunity and improve patient compliance, while micro needle patches are offering a minimally invasive, easy to distribute alternative, particularly in underserved regions. mRNA technology continues to evolve and is being adapted to encode complex tumour antigen libraries, enabling quicker and more precise vaccine design.[16] Equally important are global initiatives aiming to integrate cancer vaccines into routine immunization schedules, particularly in areas with high incidence rates of HPV and HBV related cancers. As awareness grows and new technologies mature, the emphasis remains on equity, affordability, and education, ensuring 9-09-2025 https://www.checkforplag.com Page 6/12 that cancer vaccines become a foundational tool in cancer prevention and treatment worldwide. This future forward approach underlines the crucial need for continuous innovation, public private collaboration, and policy support to bring these lifesaving technologies to the people who need them most.[17]

1.Epidemiology & Origin

Cancer refers to a large category of diseases with unchecked cell growth and the ability to infiltrate or spread to other regions of the body. Its origins are multifactorial, involving a mix of genetic mutations, environmental exposures, lifestyle factors, and in some cases, infectious agents. For example, HPV (human papillomavirus) has been directly linked to cervical and oropharyngeal cancers, while viruses such as hepatitis B and C are well-known of liver cancer. It also includes various risk factors such as tobacco and alcohol consumption, dietary habits, exposure for carcinogens (e.g., asbestos, radiation) inherited gene mutations like as BRCA1/2 in cancers such as breast and ovarian.[18] Globally,tumour is a leading cause of death, its incidence rising due to aging populations, urbanization, and changes in factor prevalence. According to the reported by the WorldHealth Organization, there were approximately twenty million new patients' cases. The most common tumour cancer worldwide includes deep lung, breast tumour, colorectal and stomach cancers, though the burden varies by region and socioeconomic status. Public health strategies now focus on both prevention (e.g., vaccines, screenings, tobacco control) and early detection, which significantly improves survival rates. Understanding the epidemiological patterns of different tumour cancers is vital for shaping world global control plans and also guiding research priorities.[19]

2. Pathology

Cancer initiates when cellular mechanisms that regulate proliferation and also death become disrupted. heart of the alter gene and epigenic mutations that gather over time, often affecting pathways like cell cycle regulation, DNA repair, apoptosis, and immune surveillance. These changes allow to proliferate uncontrollably, resist apoptosis, sustain angiogenesis, and eventually metastasize to the distant organs.[20] The pathological progression of tumour cancer typically follows several stages: starting with DNA damage caused by carcinogens and also by inherited alteration leads to the abnormal cellular changes. The abnormal cells begin to proliferate, often aided by chronic or hormonal stimuli. Progress Tumors cancer acquires additional mutations, gain invasive capabilities may spread (metastasize). Clinically, cancers tumour is highly variable in the presentation. Some, like pancreatic cancer tumour, remain asymptomatic until advanced stages, while others, like as skin cancers, are detected early due to visible changes. Systemic problem like as weight loss, fatigue may appear as the disease infection advances. Severity and behaviour a tumour depend on its histological type, grade, and stage, all of which guide treatment decisions. Certain cancers induce system effects, adding paraneoplastic syndromes, where Tumors secrete immune substances that affect other organs. Advances in molecule mechanism now allow for precise category of tumours based on biomarkers and genomic signatures, which only allow better testing but also guide targeted therapies and immunotherapy strategies. Ongoing research into tumour microenvironments,immune evasion and also metabolic reprogramming deepening our understanding of cancer biology and accelerating the development of more personalized and very usefull treatments.[21]

Vaccine Types & Preparation Methods

Types of various tumour treating Vaccines When it comes to tumour vaccines, there are five main platforms recently use for development, each with its distinct method training the know and attack tumour cells:

1. mRNA Cancer Vaccines How they work: These vaccines use synthetic mRNA to instruct the bodys cells to produce tumour specific antigens typically neoantigen striggering a targeted immune response against cancer cells. Examples: Moderna are developing personalized vaccines for melanoma, lung also

pancreatic cancers. Pros: Rapid production, customizable for individual patients and strong activation of together both T cells and aslo antibodies. Cons: Require ultracold storage and are still underdevelopment largescale validation.

2. Viral Vector Cancer Vaccines for tumour How they work: They are genetically altered viruses (like adenoviruses or poxviruses) for deliver tumour antigens into cells, prompting an immune response. Examples: Prostvac (for prostate cancer), TroVax (renal carcinoma, under development). Pros: Strong cellular immune durable immunity. Cons: Preexisting immune to vector virus may reduce effectiveness.
3. Peptide Based and their Subunit Cancer Vaccines How they work: These involve short amino acid sequences (peptides) purified tumour that initiate an immune response, often combined with an adjuvant to boost potency. Examples: NeuVax (HER2positive breast cancer), IMA901 (renal cell carcinoma). Pros: Safe, well characterized, and suitable for combination therapies. Cons: Often require multiple doses and also adjuvants; limited effectiveness standalone treatments.
4. DNA Vaccines for cancer How they work: These use circular plasmid DNA tumour antigens. Once injected into cells (often via electroporation), they initiate an immune response targeting cells. Examples: Inovios INO5401 targeting (glioblastoma) and VGX3100 (HPVrelated precancerous lesions). Pros: Stable during room temperature, manufacturing cost is very low, and easy to modify. Cons: Lower immunogenicity compared to mRNA or viral vectors, requiring delivery enhancements.
5. Dendritic Cell (DC) treatment using immunization method How they work: subjects derived dendritic cells are exposed to tumour antigens ex vivo and then reinfused into the patient, where activate cytotoxic T cells. Examples: SipuleucelT (Provenge), an FDA approved for metastatic prostate cancer Pros: Highly personalized and effective at activating T cells. Cons: Labour intensive,costly,and requires specialized facilities.[22]

Mechanism of Action

Cancer vaccines are modified to have ability for the immune system to recognize and eliminate cells that display tumour selective antigens. They work through two primary immune pathways: Humoral Immunity: Involves the formation of antibodies that bind to tumour antigens, potentially balancing cancer cells or marking them for destruction. Cellular Immunity: Activates cytotoxic T lymphocytes (CTLs) to seek and destroy cancer cells, while also helping for forming memory T cells for long-term surveillance. This dual mechanism enhances both immediate and lasting protection, making cancer vaccines a powerful tool in the immunooncology.[23] Materials Used in Cancer Vaccine Formulation Each vaccine platform uses specific materials by ensure safety, stability, and effectiveness: mRNA Vaccines: Include mRNA, lipid nanoparticles (LNPs), and stabilizers like PEG (polyethylene glycol). Vector Vaccines: Contain engineered viral vectors, capsid proteins, and stabilizing agents. Peptide/Subunit Vaccines: allow synthetic or recombinant proteins, along with adjuvants like Montanide and also MatrixM to improve immune system response. DNA Vaccines: Utilize circular plasmid DNA, often delivered via electroporation or gene gun devices, sometimes with immunostimulatory agents like CpG oligodeoxynucleotides. Dendritic Cell Vaccines: Require patientderived dendritic cells, tumour antigens (proteins or else lysates), and culture media enriched with cytokines like GMCSF for the cell maturation.[24]

7. Therapeutic function & Effectiveness

Vaccines are following an increasingly important part both in preventing cancer and existing malignancies, especially by using individualized medicine. Prevention cancer vaccines (e.g.,

HPV and hepatitis B vaccines) have demonstrated remarkable real-world efficacy: HPV vaccines (e.g., Gardasil, Cervarix) have detailed up to 99% effectiveness in prevention HPVrelated cervical and oropharyngeal cancers when administered before viral exposure. Hepatitis B vaccines can reduce the incidence of liver cancer by up to 70% in vaccinated populations. Therapeutic cancer vaccines have shown demonstrated promising application in Slowing tumour progression. Prolonging survival Boosting responsiveness for inhibitors Notable examples: SipuleucelT (Provenge) for metastatic prostate cancer extended median survival by about 4 months, with improved immune responses of body ([Kantoff et al., NEJM, 2010]). Personalized mRNA vaccines for melanoma and lung cancer have shown improved recurrencefree survival when used alongside checkpoint inhibitors in early clinical trials ([Ott et al., Nature, 2017]). Although overall effectiveness can change based on tumour type, tumour burden, and subjects' immunity status, cancer vaccines are emerging as powerful tools in multimodal cancer therapy.[10]

8. Side Effects & Adverse Events

Most cancer vaccines exhibit favourable safety profile, with various advaerse effects typically being mild to moderate and similar to immunotherapeutic agent Common adverse effects: Injection site reactions (pain, redness, swelling) Fatigue Low-grade fever Headache or flulike symptoms Muscle aches

Rare but serious adverse events include Autoimmune responses, due to overstimulation of the immune system Cytokine release syndrome (in very rare cases, especially when combined with immunotherapy) Hypersensitivity reactions to various vaccine components, particular adjuvants or delivery agents Unlike traditional chemotherapy, cancer vaccines are not cytotoxic and tend to cause fewer systemic side effects, which improves patients' quality of life during treatment. Longterm safety is under ongoing review through clinical trials and postmarketing surveillance.[25]

9. Limitations and Challenges While cancer vaccines represent enormous promise, several scientific barriers, logistical, and clinical challenges remain:

1. Tumour Heterogeneity toxin are inherently wide, and even within the similar in cance cells may determine different antigens. This makes difficult for design a universal vaccine and requires personalized approaches.[12]
2. Immunosuppressive Tumour Microenvironment Tumors can decrease immune responses locally secreting inhibitory molecules (e.g., TGF, PDL1), reducing vaccine effectiveness unless combined with checkpoint inhibitors.[12]
3. Delivery and Dosing Advanced platforms like mRNA and DNA vaccines require: Specialized delivery technologies (electroporation, lipid nanoparticles) Multiple booster doses for maintain a strong, lasting immune response
4. Cost and Accessibility Personalized cancer vaccines and dendritic cell therapies are expensive and require complex manufacturing, limiting access in low resource settings. Global inequalities in the cancer treatment remain a significant barrier to widespread adoption.
5. Detection & Biomarker Identification Therapeutic cancer vaccines demonstrate optimal efficacy when cancer is caught early. However, late stage diagnosis is still common, especially in low and middle-income countries, reducing vaccine efficacy potential.[26] Conclusion Cancer vaccines represent a strong opening in both cancer prophylactic protection and treatment. vaccines such as HPV and hepatitis B have already demonstrated high efficacy in decreasing cancer incidence, while therapeutic vaccines, particularly mRNA and dendritic cell-based therapies, are examining increasing promise in clinical trials. These vaccines can reduce tumour burden, increase survival, and improve responses when used in combination with existing immunotherapies. Though generally well tolerated, they come with logistical and clinical challenges such as tumour heterogeneity, the need for personalized approaches, delivery difficulties, and global inequities in access. Still, ongoing innovation, adding neoantigen prediction, biomarker discovery, and vaccine platform optimization, continues to accelerate progress. Ultimately, cancer vaccines are emerging as a critical pillar of precision oncology, and with further development, they may become central to standard cancer care and global cancer control strategies in the years ahead.

REFERENCE:

[1]. World Health Organization. (2023). Global strategy for cancer prevention and control through immunization. Geneva: WHO Press. ISBN 9789240065584.
[2]. Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines a new era in vaccinology. Nature Reviews Drug Discovery, 17(4), 261279.
[3]. World Health Organization. (2022). Global Vaccine Safety and Access Report: Lessons from COVID19 for Future Pandemic Preparedness. WHO Press. ISBN 9789240051235
[4]. Melief, C. J. M., van Hal, T., Aren, R., Ossendorp, F., & van der Burg, S. (2015). Therapeutic cancer vaccines. Journal of Clinical Investigation, 125(9), 34013412..
[5]. Plotkin, S., Orenstein, W., Offit, P., & Edwards, K. M. (2023). Plotkins Vaccines (8th ed.).

[6]. Elsevier. ISBN 9780323790581.
[7]. Janeway, C. A., Travers, P., Walport, M., & Shlomchik, M. J. (2021). Immunobiology: The Immune System in Health and Disease (10th ed.). Garland Science. ISBN 978081534551
[8]. Finn, O. J. (2003). Cancer vaccines: Between the idea and the reality. Nature Reviews Immunology, 3(8), 630641.
[9]. Blumberg, B. S., & London, W. T. (1982). Hepatitis B virus and primary hepatocellular carcinoma: Relationship of Icrons to cancer. Cancer Surveys, 1(1), 116.
[10]. Garland, S. M., HernandezAvila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., ... & FUTURE I Investigators. (2007). Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. 9-09-2025 https://www.checkforplag.com Page 10/12 The Lancet, 369(9574), 18611868.
[11]. Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., ... & IMPACT Study Investigators. (2010). SipuleucelT immunotherapy for castrationresistant prostate cancer. New England Journal of Medicine, 363(5), 411422.
[12]. Ott, P. A., Hu, Z., Keskin, D. B., Shula, S. A., Sun, J., Boym, D. J., ... & W, C. J. (2017). An immunogenic individual neoantigen sera for patients with melanoma. Nature, 547(7662), 217221.
[13]. Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2023). Targeting neoantigens to augment antitumour immunity. Nature Reviews Cancer, 23(3), 171187.
[14]. Brisson, M., Kim, J. J., Canfel, K., Drolet, M., Gingrs, G., Burger, E. A., ... & Hutubesy, R. (2020). Impact of HPV vaccination and cancer screening in cervical cancer elimination: a comparative modelling analysis in 78 low income countries. The Lancet, 395(10224), 575590.
[15]. Schumacher, T. N., & Schreiber, R. D. (2023). Neoantigens in cancer immunotherapy. Science, 381(6656), eabg6162.
[16]. Yarchoan, M., et al. (2023). Tumor mutational burden as a predictor of immunotherapy response. Nature Medicine, 29(1), 4455.
[17]. CouzinFrankel, J. (2023). The future of cancer vaccines. Science, 381(6656), 466469.
[18]. Kis, Z., et al. (2023). Emerging vaccine technologies for cancer prevention and treatment. Nature Biotechnology, 41(2), 156169.
[19]. Hanahan, D., & Weinberg, R. A. (2 0 1 1). H a l l m a r k s o f c a n c e r: T h e n e x t g e n e r a t i o n . C e l l , 1 4 4 (5) , 6 4 6 6 7 4 . https://doi.org/10.1016/j.cell.2011.02.013
[20]. World Health Organization. (2020). Global cancer observatory. WHO Press.
[21]. Vogelstein, B., & Kinzler, K. W. (2004). Cancer genes and the pathways they control. Nature Medicine, 10(8), 789799.
[22]. Weinberg, R. A. (2023). The Biology of Cancer (3rd ed.). Garland Science. ISBN 9781032241768. 22. Sahin, U., & Treci, . (2023). Cancer Vaccines: From Bench to Bedside. Nature Reviews Drug Discovery, 22(3), 189210.
[23]. Melief, C. J., et al. (2023). Cancer Immunotherapy: Immune Mechanisms and Vaccine Strategies. Annual Review of Immunology, 41, 130.
[24]. Pollard, A. J., & Bijker, E. M. (2021). Vaccine Design: Materials and Production Methods. Nature Reviews Immunology, 21(8), 463479.
[25]. Postow, M. A., et al. (2021). Immunerelated adverse events associated with cancer immunotherapy. Nature Reviews Disease Primers, 7(1), 121. 26. Sawyers, C. L. (2023). Cancer biomarkers: Current status and future directions. Nature Reviews Cancer, 23(5), 295312